Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

NCT00244972 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

74

Enrollment

NIH

Sponsor class

Conditions

Advanced Malignant Neoplasm

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Sorafenib Tosylate
DRUG: Tipifarnib

Sponsor

National Cancer Institute (NCI)